Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Insilico Medicine is a clinical-stage artificial intelligence (AI)-driven drug discovery and development company. Leveraging its proprietary Pharma.AI platform, which spans biology, chemistry, and clinical development analysis, Insilico aims to accelerate the creation of innovative medicines for unmet medical needs. The company focuses on discovering and developing novel therapeutics for cancer, fibrosis, immunology, central nervous system (CNS) diseases, and aging-related diseases. Insilico Medicine has a pipeline of internally discovered therapeutic programs, with several candidates advancing to clinical trials. Their mission is to accelerate drug discovery and development through advanced AI and make novel treatments more rapidly available to patients.
Serves as the global headquarters, overseeing strategic direction, core AI research and development, and international operations for drug discovery programs.
Located within the Hong Kong Science Park, a premier hub for innovation and technology, offering state-of-the-art facilities and fostering collaboration within a vibrant R&D ecosystem.
A dynamic, fast-paced, and highly collaborative environment driven by scientific excellence and innovation. The culture encourages interdisciplinary teamwork among AI specialists, biologists, chemists, and clinical researchers with a shared mission to revolutionize drug discovery.
Strategically positioned in Asia's burgeoning biotech landscape, providing access to a rich talent pool, investment opportunities, and collaborative partnerships. Hong Kong's robust infrastructure and government support for R&D enhance its role as a global innovation center.
Insilico Medicine operates globally with a network of offices and research centers across North America (USA, Canada), Asia (Hong Kong, Shanghai, Seoul), and the Middle East (UAE). This international footprint supports diverse functions including AI-driven R&D, preclinical and clinical drug development, business development, strategic partnerships, and talent acquisition worldwide.
Units 518-528, 5/F, Bio-Informatics Centre, No. 2 Science Park West Avenue
Shatin
New Territories
Hong Kong
Address: 99 Hudson Street, 5th Floor, New York, NY 10013
Expanding presence in the major US pharmaceutical market, engaging with regulatory bodies like the FDA, and fostering partnerships with US-based research institutions and companies.
Address: Room 1002, Building 1, Lane 555, Chuanqiao Road, Pudong New Area, Shanghai
Driving drug discovery and development efforts for the Asian market, particularly China, and collaborating with local academic and industry partners.
Address: Office 209, 2nd Floor, Building A3, Al Maqam Tower, ADGM Square, Al Maryah Island, Abu Dhabi
Expanding research capabilities and exploring strategic partnerships and collaborations in the Middle East and North Africa (MENA) region, leveraging regional investments in technology and healthcare.
Address: 6666 Rue Saint-Urbain #300, Montreal, Quebec H2S 3H1
Strengthening R&D footprint in North America, focusing on AI innovation and collaboration with Canadian research institutions and AI talent.
Address: #428, 4F, Bio-shared office space, 21, Baekbeom-ro 31-gil, Mapo-gu, Seoul
Expanding presence and partnerships in the dynamic South Korean biotech market, facilitating regional collaborations and clinical research activities.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Insilico Medicine' leadership includes:
Insilico Medicine has been backed by several prominent investors over the years, including:
Insilico Medicine has made several key appointments to its executive team over the past 12 months, significantly strengthening its leadership in finance, clinical development, and strategy to support its ongoing growth and the advancement of its AI-driven drug discovery pipeline. No major executive departures have been publicly announced during this period.
Discover the tools Insilico Medicine uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Insilico Medicine commonly uses standard corporate email formats, primarily [firstname].[lastname]@insilico.com. Variations like [firstinitial][lastname]@insilico.com may also be in use. For example, a person named Jane Doe might have an email address like jane.doe@insilico.com.
[firstname].[lastname]@insilico.com or [f][lastname]@insilico.com
Format
jane.doe@insilico.com
Example
75%
Success rate
Business Wire • May 16, 2024
Insilico Medicine announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, to co-develop novel therapeutics for various types of cancer using Insilico's AI platform and NCI's expertise....more
GlobeNewswire • April 23, 2024
Insilico Medicine presented positive topline data from its Phase I clinical trial of ISM3091, an AI-discovered and AI-developed TNFa inhibitor for rheumatoid arthritis. The study demonstrated good safety, tolerability, and favorable pharmacokinetics....more
Business Wire • April 2, 2024
Insilico Medicine announced the appointment of Keith Mikule, CPA, as its new Chief Financial Officer. Mr. Mikule brings over 20 years of financial leadership experience in the biotechnology and pharmaceutical industries....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Insilico Medicine, are just a search away.